Idorsia Expands QUVIVIQ Reach with Saudi Arabia and Levant Deal
Event summary
- Idorsia partners with Jamjoom Pharma for QUVIVIQ distribution in Saudi Arabia and the Levant region.
- Exclusive agreement covers commercialization, regulatory, and distribution responsibilities for Jamjoom Pharma.
- Idorsia receives upfront payment plus royalties on net sales under the deal.
- QUVIVIQ is marketed by Idorsia in North America and Europe, with partnerships in Asia-Pacific, Middle East, and Latin America.
The big picture
This partnership aligns with Idorsia’s strategy of leveraging regional experts to expand QUVIVIQ’s global footprint. The deal underscores the growing importance of localized commercialization strategies in pharmaceutical markets, particularly in regions with complex regulatory environments like Saudi Arabia and the Levant.
What we're watching
- Regulatory Execution
- Whether Jamjoom Pharma can navigate local regulatory hurdles to expedite QUVIVIQ's market entry.
- Market Penetration
- The pace at which Idorsia and Jamjoom Pharma can establish QUVIVIQ as a leading insomnia treatment in the region.
- Revenue Impact
- How royalties from this deal will contribute to Idorsia's global revenue growth.
Related topics